Skip to content

Price / book at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
+4.3×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
1.5×+0.3×
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
4.6×+2.9×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
3.6×-5.6×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
4.4×+2.2×
Alumis Inc. logo
Alumis Inc.ALMS
4.9×+3.0×

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+269%
Enterprise value$700.21M+188%
P/S159.6×+89.0×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Calculated from DBV Technologies’s reported figures.

Based on the most recent quarter.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's price / book?
DBV Technologies (DBVT) reported price / book of 5.6× in Q1 2026.
How has DBV Technologies's price / book changed year-over-year?
DBV Technologies's price / book decreased by 88.4% year-over-year, from 48.2× to 5.6×.
What is the long-term trend for DBV Technologies's price / book?
Over 5 years (2020 to 2025), DBV Technologies's price / book has grown at a 26.6% compound annual growth rate (CAGR), from 1.4× to 4.6×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.